Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00514501 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

A Phase 2 study of Acute Coronary Syndrome, sponsored by Molecular Insight Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
510
Enrollment target
20
Study locations

NCT00514501 is a Phase 2 study of Acute Coronary Syndrome that has completed, run by Molecular Insight Pharmaceuticals. The registered enrollment target is 510 participants, below the 2,709-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00514501, a Phase 2 study of Acute Coronary Syndrome, has completed, sponsored by Molecular Insight Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
510 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia. Readers independent of the clinical study centers will review results of imaging studies in a blinded fashion at an imaging core lab. The resulting independent reading of the images will be compared against the truth standard for ACS.

Conditions Studied

Acute Coronary Syndrome

Interventions

  • DRUG Iodofiltic acid I 123

Study Locations (20)

California

  • - Los Angeles
  • - Mission Viejo
  • - Newport Beach
  • - Roseville

Michigan

  • - Detroit
  • - Royal Oak
  • - Troy

Alabama

  • - Birmingham
  • - Huntsville

Connecticut

  • - Hartford
  • - New Haven

Illinois

  • - Aurora
  • - Maywood

Arizona

  • - Mesa

Delaware

  • - Newark

Florida

  • - Jacksonville

Trial Details

FieldValue
Enrollment Target 510 participants
Start Date 2007-05
Est. Completion 2008-12
Phase Phase 2

Sponsor

Molecular Insight Pharmaceuticals

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00514501

The ClinicalTrials.gov registry entry for NCT00514501 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,709-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (81% lower). The listed sponsor is Molecular Insight Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Iodofiltic acid I 123 is the first listed.

NCT00514501 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Alabama.

Frequently Asked Questions

What is clinical trial NCT00514501 about?

NCT00514501 is a clinical study titled "Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome". This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia. Readers independent of the clinical study centers will review results of imaging ...

What is the current status of trial NCT00514501?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2007-05. Estimated completion is 2008-12.

What conditions does trial NCT00514501 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT00514501?

The interventions under investigation include: Iodofiltic acid I 123 (DRUG).

Who is sponsoring clinical trial NCT00514501?

This trial is sponsored by Molecular Insight Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00514501 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Coronary Syndrome

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.